cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5.

Biochem J

Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232-0615, USA.

Published: June 2003

The physiological effects of cGMP are largely determined by the activities of intracellular receptors, including cGMP-dependent protein kinase (PKG) and cGMP-binding cyclic nucleotide phosphodiesterases (PDEs), and the distribution of cGMP among these receptors dictates activity of the signalling pathway. In the present study, the effects of PKG-Ialpha or PKG-Ibeta on the rate of cGMP hydrolysis by the isolated PDE5 catalytic domain were examined. PKG-Ialpha strongly inhibited cGMP hydrolysis with an IC(50) value of 217 nM, which is similar to the physiological concentration of PKG in pig coronary artery reported previously. By contrast, PKG-Ibeta, which has lower affinity for cGMP than does PKG-Ialpha, inhibited cGMP hydrolysis with an IC(50) of approx. 1 microM. Inhibition by PKG-Ialpha was more effective than that by PKG-Ibeta, consistent with their relative affinities for cGMP. Autophosphorylation of PKGs increased their cGMP-binding affinities and their inhibitory effects on PDE5 hydrolysis of cGMP. Autophosphorylation of PKG-Ibeta increased its inhibitory potency on PDE5 hydrolysis of cGMP by 10-fold compared with a 2-fold increase upon autophosphorylation of PKG-Ialpha. The results indicate that cGMP bound to allosteric cGMP-binding sites of PKG is protected from hydrolysis by PDE5 and that persistent protection of cGMP by either non-phosphorylated or autophosphorylated PKGs may be a positive-feedback control to sustain cGMP signalling.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1223414PMC
http://dx.doi.org/10.1042/BJ20030107DOI Listing

Publication Analysis

Top Keywords

cgmp hydrolysis
16
cgmp
13
cgmp-dependent protein
8
protein kinase
8
pkg-ialpha inhibited
8
inhibited cgmp
8
hydrolysis ic50
8
cgmp autophosphorylation
8
pde5 hydrolysis
8
hydrolysis cgmp
8

Similar Publications

The carboxyl terminus of Hsc70-interacting protein (CHIP) is pivotal for managing misfolded and aggregated proteins via chaperone networks and degradation pathways. In a preclinical rodent model of CHIP-related ataxia, we observed that CHIP mutations lead to increased levels of phosphodiesterase 9A (PDE9A), whose role in this context remains poorly understood. Here, we investigated the molecular mechanisms underlying the role of PDE9A in CHIP-related ataxia and demonstrated that CHIP binds to PDE9A, facilitating its polyubiquitination and autophagic degradation.

View Article and Find Full Text PDF

Phosphodiesterase 2 A (PDE2A) function is stimulated by cGMP to catabolize cAMP. However, neurological and neurochemical effects of PDE2A deficiency are poorly understood. To address this gap, we studied behavioral characteristics and cerebral morpho-chemical changes of adult male heterozygous C57BL/6-PDE2A+/- (HET), and wild type C57BL/6-PDE2A+/+ (WT) mice.

View Article and Find Full Text PDF

Multimodal action of phosphodiesterase 5 inhibitors against neurodegenerative disorders: An update review.

J Biochem Mol Toxicol

November 2024

Division of Pharmacology, Institute of Pharmaceutical Research, GLA University, Chaumuhan, Mathura, India.

Article Synopsis
  • - PDE5 is an enzyme that breaks down cGMP, a molecule crucial for enhancing neural signals and influencing learning and memory processes, and it's found in the brain and in the smooth muscle of the corpus cavernosum.
  • - PDE5 inhibitors, which prevent the breakdown of cGMP, can enhance nitric oxide effects, providing anti-inflammatory and neuroprotective benefits, potentially addressing neurodegenerative disorders, which currently lack curative treatments.
  • - The review explores how PDE5 inhibitors may act as disease-modifying agents for conditions like Alzheimer's and Parkinson's diseases by simultaneously influencing both cAMP and cGMP pathways, potentially improving neurological functions.
View Article and Find Full Text PDF

Background: Phosphodiesterases (PDEs) are enzymes that catalyze the hydrolysis of cyclic adenosine monophosphate AMP (cAMP) and/or cyclic guanosine monophosphate (cGMP). PDE inhibitors can mitigate chronic pain and depression when these disorders occur individually; however, there is limited understanding of their role in concurrent chronic pain and depression. We aimed to evaluate the mechanisms of action of PDE using 2 mouse models of concurrent chronic pain and depression.

View Article and Find Full Text PDF

Patients with autoimmune disease-related interstitial lung disease may develop pulmonary fibrosis, which may become progressive. Progressive pulmonary fibrosis (PPF) is associated with poor outcomes. Antifibrotic therapies have shown efficacy as treatments for PPF in patients with autoimmune diseases, but new treatments are needed to slow or halt disease progression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!